BiotechTube
Bitterroot Bio

Bitterroot Bio

San Francisco, United States· Est.
brbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $155M

Overview

Bitterroot Bio is an early-stage biotech focused on translating immuno-oncology principles to treat cardiovascular disease (CVD), specifically atherosclerosis. The company's core hypothesis is that blocking the 'don't eat me' signal CD47 on harmful cells within arterial plaques will enhance macrophage clearance and halt disease progression. With a world-class scientific founding team and backing from top-tier life science investors, Bitterroot aims to develop first-in-class cardio-immunotherapies. The company is currently in the preclinical/early clinical development stage, positioning itself at the forefront of a potentially transformative new therapeutic paradigm.

Cardiovascular DiseaseAtherosclerosis

Technology Platform

Cardio-immunology platform targeting the CD47-SIRPα 'don't eat me' pathway to enhance macrophage clearance of atherosclerotic plaque components.

Funding History

2
Total raised:$155M
Series A$145M
Seed$10M

Opportunities

The company operates in the vast, underserved cardiovascular market where a significant residual inflammatory risk persists despite lipid-lowering therapies, creating a multi-billion dollar opportunity for disease-modifying treatments.
Successfully translating an immuno-oncology mechanism to cardiology could establish a first-in-class therapy and define the cardio-immunology field, making Bitterroot an attractive strategic partner or acquisition target.

Risk Factors

The lead anti-CD47 program carries high biological risk, as the mechanism must prove safe for chronic use and effective at modifying plaque in humans, a challenging translational hurdle.
The company faces intense competition from other anti-inflammatory approaches and will require enormous capital to fund late-stage cardiovascular outcome trials, presenting significant clinical and financial execution risks.

Competitive Landscape

Bitterroot competes in the emerging cardio-immunology space against companies developing other anti-inflammatory agents (e.g., targeting IL-6, Lp(a)) and faces competition from the repurposed generic drug colchicine. Its most direct competitors are other biotechs exploring macrophage-targeted therapies for atherosclerosis, but its specific focus on CD47 provides a distinct, though unproven, mechanistic approach.

More companies in Biologics / Biosimilars →More companies in United States →